BioMarin Pharmaceutical Inc, a developer of genetic therapies with eight commercial therapies for rare genetic disorders, has appointed Greg Friberg as chief Research & Development officer and James Sabry as chief business officer. Dr Friberg will join BioMarin on September 30 from Amgen Inc where he was most recently vice president, global medical affairs, rare disease and also served as head of global development for the company's haematology/oncology and bone portfolios.
Dr Friberg holds an MD from New York Medical College and served on the faculty of the University of Chicago, both US. He succeeds Hank Fuchs who is retiring after 15 years at BioMarin and who led the development of five new medicines. Dr Sabry, whose appointment is effective on October 7, joins BioMarin from Roche and Genentech, serving most recently as global head of Roche Partnering. He holds an MD from Queen's University, Canada and a PhD in neuroscience from the University of California, San Francisco, US.
BioMarin announced the appointments on 21 August 2024.